Linked Life Data

16403638

Source:http://linkedlifedata.com/resource/pubmed/id/16403638

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2006-3-20
pubmed:abstractText
Glucose analogues 5 and 9 of E5564 were synthesized, and their LPS-antagonistic activities were measured. The inhibitory activities (IC50) on LPS-induced TNFalpha production of these two compounds towards human whole blood cells were 0.06 and 0.83 nM, respectively. Inhibitory doses (ID50) of compounds 5 and 9 on TNFalpha production induced by coinjection of galactosamine and LPS in C3H/HeN mice in vivo were measured and were 0.55 and <0.20 mg/kg, respectively. And also C3H/HeN mice preinjected with compounds 5 and 9 were protected from lethality induced by coinjection of galactosamine and LPS; out of eight mice preinjected with 1 mg/kg of the compounds, one-six and three of eight mice were protected, respectively.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0968-0896
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3011-6
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Syntheses of glucose analogues of E5564 as a highly potent anti-sepsis drug candidate.
pubmed:affiliation
Chemistry Department, Chemtech Labo., Inc., Hiromachi 1-2-58, Shinagawa-ku, Tokyo 140-8710, Japan. shioza@shina.sankyo.co.jp
pubmed:publicationType
Journal Article